Navigation Links
Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Date:7/28/2011

n 2010.

The share of profits from associates was euro 570 million, up 16.1% compared to H1 2010, due to a 15.4% rise in the share of after-tax profits from the territories managed by BMS under the Plavix® and Avapro® alliance (euro 548 million).

Net income attributable to non-controlling interests was euro 136 million, down 8.1% due to competition from clopidogrel generics in Europe (profits paid to BMS from territories managed by Sanofi were euro 125 million, down 8.8%).

Business operating income reached euro 5,972 million, a decrease of 12.7%, or 12.4% at constant exchange rates.

Net financial expenses were euro 178 million versus euro 140 million in H1 2010, despite the acquisition of Genzyme. Net financial expenses also included a capital gain of euro 47 million on the sale of the stake in Novexel booked in the first quarter 2010.

First-half effective tax rate was 27.5% compared with 28.2% in H1 2010.

Business net income(1) was euro 4,320 million, a decrease of 11.9%, or 11.5% at constant exchange rates. The ratio of business net income(1) to net sales was 26.8% compared to 30.3% in H1 2010.

Business earnings per share(1) (EPS) was euro 3.30, a decrease of 12.2% over H1 2010 figure of euro 3.76. At constant exchange rates, business earnings per share(1) decreased by 11.7%.

(1) See Appendix 10 for definitions of financial indicators, and Appendix 6 for reconciliation of business net income to consolidated net income attributable to equity holders of Sanofi

From business net income to consolidated net income (see Appendix 6) In H1 2011, the main reconciling items between business net income and consolidated net income attributable to equity holders of Sanofi were:

  • A euro 1,701 million amortization charge against intangible assets arising on the application of purchase accounting to a
    '/>"/>

  • SOURCE Sanofi
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. New Senior Executives Appointed at Sanofi:
    2. VR Business Sales, Mergers & Acquisitions Charlotte Completes Sale of Penrod Medical Equipment
    3. Global Medical Devices Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Marketing Spend and Sales Strategies
    4. TPI Ships Macrolide API Samples for International Sales Standard Testing
    5. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
    6. Burlington Medical Supplies Reorganizes Sales and Marketing Operations
    7. HASCO Medical Inc. Names Mike Dumais the Vice President of Sales for Southern Medical and Mobility
    8. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
    9. With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing
    10. TPI Signs Macrolide API International Sales and Marketing Agreement
    11. CellerateRX TV Commercials Begin Airing on Fox News Network via Geraldo at Large and Fox News Sunday Programs, Expanding the Direct-To-Consumer Sales Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/1/2015)... , June 1, 2015  Diomics, an innovator in ... Weissman , global financial executive, has joined Diomics, board ... more than 25 years of industry experience in broad ... as a managing director at Credit Suisse and JP ... Stanley/Dean Witter. "Diomics is on the forefront ...
    (Date:6/1/2015)... Research and Markets  ( http://www.researchandmarkets.com/research/4lw2mn/global_a_dialyzer ) ... A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor ) ... The Global A Dialyzer Reprocessing Machine ... a professional and in-depth study on the current ... The report provides a basic overview of ...
    (Date:6/1/2015)... BROOK, N.J. , June 1, 2015 /PRNewswire/ ... Food and Drug Administration (FDA) has accepted for ... for Anthim® (obiltoxaximab) for the treatment and prevention ... was submitted on March 20, 2015. Anthim is ... National Stockpile, the U.S. government,s repository of critical ...
    Breaking Medicine Technology:Richard M. Weissman joins Diomics Board of Directors 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
    ... March 19 FluoroPharma Inc., a company,developing breakthrough ... (PET) market, announced commencement of Phase,I clinical trials ... the proposed studies. The Phase I trial is ... safety, distribution and dosimetry,of BFPET as a PET ...
    ... KNOLLS, N.J., March 19 Emisphere,Technologies, Inc. (Nasdaq: ... studies demonstrating that its proprietary eligen(R) technology,enhances the ... than were,used previously. The lower doses are believed ... the rate of absorption of B12 administered,with eligen(R) ...
    Cached Medicine Technology:FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses 2Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses 3
    (Date:6/1/2015)... June 02, 2015 The National ... Willey as a 2015-2016 inductee into its VIP ... with this prestigious distinction for leadership in safety, environment, ... networking organization exclusively for professional women, boasting more than ... "I’m pleased to present Lourinda with this important honor,” ...
    (Date:6/1/2015)... 02, 2015 Dr. Robert ... Piedmont Physical Medicine & Rehabilitation, P.A., has published ... of stem cell therapy for knees, and highlights ... preferred alternative to arthroscopy or knee joint replacement. ... of Neuromusculoskeletal, Vascular and Regenerative Medicine, writes that ...
    (Date:6/1/2015)... 01, 2015 Atagi Plastic Surgery and ... named an Ultherapy® Ultra Treatment Provider by ... Skin Aesthetics is one of only six practices in ... treatment provider. , Atagi Plastic Surgery and Skin ... area has led the practice to earn the distinction ...
    (Date:6/1/2015)... 2015 The Muscular Dystrophy Association ... in participating in the sold out 2015 Bank ... secure guaranteed entry by signing up through the ... space is limited. , This national endurance program ... and abilities, and a supportive community of teammates, ...
    (Date:6/1/2015)... (PRWEB) June 01, 2015 Note: Dr. ... development in breast cancer prevention. , A phase III ... that postmenopausal women with ductal carcinoma in situ (DCIS) ... and prevention. , The study (NSABP B-35/NRG Oncology) looked ... completed the standard five-year treatment with tamoxifen to those ...
    Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Sold Out 2015 Bank of America Chicago Marathon and Marine Corps Marathon Entries Still Available through MDA Team Momentum 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3
    ... complication that can occur in children affected by acute ... attack, pulmonary embolism and other cardiovascular diseases//. ... Italy by the Laboratory of Genetic and Environmental Epidemiology ... collaboration with the Haematology Division of the University of ...
    ... Prexige is said to be linked to an increased risk ... warned to exercise caution in its use.// ,The ... Prexige (generic name, lumiracoxib) available from Tuesday. The drug is ... it was found in 2004 that these group of drugs ...
    ... have suggested that cross-immunity created in response to infection ... //,by related serotypes thus leading to the waxing and ... help understand the pattern of this deadly mosquito-borne illness ... 1980s, there's been a sequential replacement of the dominant ...
    ... Indiana University School of Medicine it was found that ... the life span of those suffering from compromised immune ... the journal of Biological Chemistry. These proteins can be ... boost the patient’s immune system. The lead researcher Roman ...
    ... been criticized severely because a staff nurse has refused to send ... Mary Smith, 87 had an agonizing pain in her lower abdomen. ... replied that she could not have an ambulance and had to ... her. Then when the GP arrived he just gave her some ...
    ... minds of many cancer survivors. After treatment, as life ... makers now //,consider a chronic condition, survivors need to ... choices to ensure quality-of-life. This national movement, commonly referred ... year. ,Steps for Living (SFL), a nonprofit ...
    Cached Medicine News:Health News:Thrombosis, a Serious Risk in Children with Leukemia 2Health News:New Arthritis Drug Linked to Increased Risk of Heart Attacks 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 3Health News:New Music Project Promotes Quality-of-Life After Cancer 2
    ... Easyfield is lightweight enough to shuttle ... carrying case. Designed with a goldmann standard ... fixed-point grid with 79 locations (including 30-2, ... and 3 different suprathresholds out to 30. ...
    The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
    ... additional hardware and software features to meet ... clinics or teaching institutions. Standard with B/Y ... for experimental or clinical studies. Ethernet connection ... further tests including Flicker- and Color perimetry, ...
    ... Designed around the patented ... Octopus 301 sets the trend ... decade. Ideal for routine screening ... performance, accuracy and quality ...
    Medicine Products: